Arvinas to Participate in Upcoming Investor Conferences
03 juin 2024 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain
28 mai 2024 09h00 HE
|
Precision Neuroscience
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface company Precision Neuroscience Corporation (Precision) and a neurosurgery team from the Mount Sinai Health System now hold the...
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
28 mai 2024 08h00 HE
|
Neurona Therapeutics
Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
Precision Neuroscience Expands Clinical Research In Brain–Computer Interface
22 mars 2024 08h30 HE
|
Precision Neuroscience
NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at...
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
07 mars 2024 07h00 HE
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
27 févr. 2024 08h00 HE
|
Healis Therapeutics
CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
15 févr. 2024 08h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a...
Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego
12 févr. 2024 08h00 HE
|
Healis Therapeutics
Healis' clinical program developing BoNT/A neuromodulator proteins has the potential to transform care for over 280 million patients with depression.
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
07 févr. 2024 08h00 HE
|
Fundamental Pharma GmbH
PRESS RELEASE FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic...
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
05 févr. 2024 07h00 HE
|
NodThera
Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...